Treatment strategies for early rheumatoid arthritis

Current Opinion in Rheumatology

Volumn 25, Issue 3, 2013, Pages 375-383

  Bykerk, Vivian P ^a   Schoels, Monika M ^b  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

^b Hietzing Hospital   (Austria)

Author keywords

rheumatoid arthritis; treat to target; treatment strategies

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; SALAZOSULFAPYRIDINE; STROMELYSIN; TUMOR NECROSIS FACTOR INHIBITOR;

CARDIOVASCULAR RISK; COMORBIDITY; DAS28; EARLY INTERVENTION; FIBROMYALGIA; HUMAN; LUNG DISEASE; META ANALYSIS (TOPIC); MOLECULARLY TARGETED THERAPY; MONOTHERAPY; OSTEOARTHRITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL AGENTS; BIOLOGICAL MARKERS; COMBINED MODALITY THERAPY; HUMANS; PROGNOSIS; SECONDARY PREVENTION; TREATMENT OUTCOME;

EID: 84875881513     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0b013e32835fd294     Document Type: Review

References (54)

1. Silman Alan J, Hochberg Marc C. Epidemiology of the rheumatic diseases. 2nd ed Oxford, NY: Oxford University Press; 2001.
2. Crowson CS, Matteson EL, Myasoedova E, et al. The lifetime risk of adultonset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis Rheum 2011; 63:633-639.
3. Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological diseasemodifying antirheumatic drugs. Ann Rheum Dis 2010; 69:964-975.
4. Smolen JS, Aletaha D, Bijlsma JWJ, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010; 69:631-637.
5. Schoels M, Knevel R, Aletaha D, et al. Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. Ann Rheum Dis 2010; 69:638-643.
6. Fransen J, Bernelot Moens H, Speyer I, et al. Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicenter, cluster randomised control trial. Ann Rheum Dis 2005; 64:1294-1298.
7. Grigor C, Capell H, Stirling A, et al. Effect of a treatment Strategy of Tight Control for Rheumatoid Arthritis (the TICORA study): a single-blind, randomised controlled trial. Lancet 2004; 364:263-269.
8. Stenger AA, van Leeuwen MA, Houtman PM, et al. Early effective suppression of inflammation in rheumatoid arthritis reduces radiographic progression. Br J Rheumatol 1998; 37:1157-1163.
9. Verstappen SM, Jacobs JW, van der Veen MJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA), an openlabel strategy trial. Ann Rheum Dis 2007; 66:1443-1449.
10. van Tuyl LH, Lems WF, Voskuyl AE, et al. Tight control and intensified COBRA combination treatment in early rheumatoid arthritis: 90% remission in a pilot trial. Ann Rheum Dis 2008; 67:1574-1577.
11. Soubrier M, Lukas C, Sibilia J, et al. Disease activity score-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis: data from the GUEPARD trial and ESPOIR cohort. Ann Rheum Dis 2011; 70:611-615.
12. Symmons D, Tricker K, Roberts C, et al. The British Rheumatoid Outcome Study Group (BROSG) randomised controlled trial to compare the effectiveness and cost-effectiveness of aggressive versus symptomatic therapy in established rheumatoid arthritis. Health Technol Assess 2005; 9:1-78; iii-iv; ix-x.
13. BakkerMF, Jacobs JW, Welsing PM, et al. Early clinical response to treatment predicts 5-year outcome in RA patients: follow-up results from the CAMERA study. Ann Rheum Dis 2011; 70:1099-1103.
14. Bakker MF, Jacobs JW, Welsing PM, et al. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. Ann Intern Med 2012; 156:329-339.
15. Klarenbeek NB, Gü ler-Yü ksel M, van der Kooij SM, et al. The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study. Ann Rheum Dis 2011; 70:1039-1046.
16. van der Kooij SM, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, et al. Drugfree remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis. Ann Rheum Dis 2009; 68:914-921.
17. Rantalaiho V, Korpela M, Hannonen P, et al. for the FINRaCO group. The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial. Arthritis Rheum 2009; 60:1222-1231.
18. van der Heijde D, Breedveld FC, Kavanaugh A, et al. Disease activity, physical function, and radiographic progression after longterm therapy with adalimumab plus methotrexate: 5-year results of PREMIER. J Rheumatol 2010; 37:2237-2246.
19. Emery P, Mease PJ, Rubbert-Roth A, et al. Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: a retrospective pooled analysis. Rheumatol 2011; 50:2223-2232.
20. van Eijk IC, Nielen MM, van der Horst-Bruinsma I, et al. Aggressive therapy in patients with early arthritis results in similar outcome compared with conventional care: the STREAM randomized trial. Rheumatol 2012; 51:686-694.
21. Vermeer M, Kuper HH, Hoekstra M, et al. Implementation of a treat-to-target strategy in very early rheumatoid arthritis: results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort study. Arthritis Rheum 2011; 63:2865-2872.
22. Schipper LG, Vermeer M, Kuper HH, et al. A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: a study of two cohorts in the Dutch Rheumatoid Arthritis Monitoring registry. Ann Rheum Dis 2012; 71:845-850.
23. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Kerstens PJ, et al. DAS-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis. Ann Rheum Dis 2010; 69:65-69.
24. Urata Y, Uesato R, Tanaka D, et al. Treating to target matrix metalloproteinase 3 normalisation together with disease activity score below 2.6 yields better effects than each alone in rheumatoid arthritis patients: T-4 study. Ann Rheum Dis 2012; 71:534-540.
25. Gullick NJ, Oakley SP, Zain A, et al. Goal-directed therapy for RA in routine practice is associated with improved function in patients with disease duration up to 15 years. Rheumatol 2012; 51:759-761.
26. Moreland LW, O'Dell JR, Paulus HE, et al. for the TEAR investigators. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the Treatment of Early Aggressive Rheumatoid Arthritis trial. Arthritis Rheum 2012; 64:2824-2835.
27. Schipper LG, Kievit W, den Broeder AA, et al. Treatment strategies aiming at remission in early rheumatoid arthritis patients: starting with methotrexate monotherapy is cost-effective. Rheumatol 2011; 50:1320-1330.
28. Aletaha D, Alasti F, Smolen JS, et al. Rheumatoid factor determines structural progression of rheumatoid arthritis dependent and independent of disease activity. Ann Rheum Dis 2012. [Epub ahead of print]
29. Boers M, van Tuyl L, van den Broek M, et al. Meta-analysis suggests that intensive nonbiological combination therapy with step-down prednisolone (COBRA strategy) may also 'disconnect' disease activity and damage in rheumatoid arthritis. Ann Rheum Dis 2013; 72:406-409.
30. Detert J, Bastian H, Listing J, et al. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study. Ann Rheum Dis 2012. [Epub ahead of print]
31. van Vollenhoven RF, Ernestam S, Geborek P, et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (SWEFOT trial): 1-year results of a randomized trial. Lancet 2009; 374:459-466.
32. Rezai H, Saevarsdottir S, Forslind K, et al. In early rheumatoid arthritis, patients with a good initial response to methotrexate have excellent 2-year clinical outcomes, but radiological progression is not fully prevented: data from the methotrexate responders population in the SWEFOT trial. Ann Rheum Dis 2012; 71:186-191.
33. van Vollenhoven RF, Geborek P, Forslind K, et al. Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2-year follow-up of the randomised, nonblinded, parallelgroup SWEFOT trial. Lancet 2012; 379:1712-1720.
34. Edmonds J, Lassere M, Sharp JT, et al. Objectives study in RA (OSRA): a RCT defining the best clinical target for disease activity control in RA. Ann Rheum Dis 2007; 66 (Suppl II):325.
35. van der Heijde D, Klareskog L, Boers M, et al. Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results. Ann Rheum Dis 2005; 64:1582-1587.
36. Aletaha D, Smolen JS. Joint damage in rheumatoid arthritis progresses in remission according to the disease activity score in 28 joints and is driven by residual swollen joints. Arthritis Rheum 2011; 63:3702-3711.
37. Ma MH, Scott IC, Kingsley GH, et al. Remission in early rheumatoid arthritis. J Rheumatol 2010; 37:1444-1453.
38. Dougados M, Devauchelle-Pensec V, Ferlet JF, et al. The ability of synovitis to predict structural damage in rheumatoid arthritis: a comparative study between clinical examination and ultrasound. Ann Rheum Dis 2012. [Epub ahead of print]
39. Hama M, Uehara T, Takase K, et al. Power Doppler ultrasonography is useful for assessing disease activity and predicting joint destruction in rheumatoid arthritis patients receiving tocilizumab-preliminary data. Rheumatol Int 2012; 32:1327-1333.
40. Fukae J, Isobe M, Kitano A, et al. Radiographic prognosis of finger joint damage predicted by early alteration in synovial vascularity in patients with rheumatoid arthritis: potential utility of power Doppler sonography in clinical practice. Arthritis Care Res 2011; 63:1247-1253.
41. Fukae J, Kon Y, Henmi M, et al. Change of synovial vascularity in a single finger joint assessed by power doppler sonography correlated with radiographic change in rheumatoid arthritis: comparative study of a novel quantitative score with a semiquantitative score. Arthritis Care Res 2010; 62:657-663.
42. Naredo E, Moller I, Cruz A, et al. Power Doppler ultrasonographic monitoring of response to antitumor necrosis factor therapy in patients with rheumatoid arthritis. Arthritis Rheum 2008; 58:2248-2256.
43. Pascual-Ramos V, Contreras-Yanez I, Cabiedes-Contreras J, et al. Hypervascular synovitis and American College of Rheumatology Classification Criteria as predictors of radiographic damage in early rheumatoid arthritis. Ultrasound Quarter 2009; 25:31-38.
44. Foltz V, Gandjbakhch F, Etchepare F, et al. Power Doppler ultrasound, but not low-field magnetic resonance imaging, predicts relapse and radiographic disease progression in rheumatoid arthritis patients with low levels of disease activity. Arthritis Rheum 2012; 64:67-76.
45. Bugatti S, Manzo A, Caporali R, et al. Assessment of synovitis to predict bone erosions in rheumatoid arthritis. Ther Adv Musculoskelet Dis 2012; 4:235-244.
46. Suter LG, Fraenkel L, Braithwaite RS. Role of magnetic resonance imaging in the diagnosis and prognosis of rheumatoid arthritis. Arthritis Care Res 2011; 63:675-688.
47. Kerola AM, Kerola T, Kauppi MJ, et al. Cardiovascular comorbidities antedating the diagnosis of rheumatoid arthritis. Ann Rheum Dis 2012. [Epub ahead of print]
48. Peters MJL, Symmons DPM, McCarey D, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010; 69:325-331.
49. John H, Hale ED, Treharne GJ, et al. Patient evaluation of a novel patient education leaflet about heart disease risk among people with rheumatoid arthritis. Musculoskelet Care 2011; 9:194-199.
50. Paccou J, Brazier M, Mentaverri R, et al. Vascular calcification in rheumatoid arthritis: prevalence, pathophysiological aspects and potential targets. Atherosclerosis 2012; 224:283-290.
51. Onat A, Direskeneli H, et al. Excess cardiovascular risk in inflammatory rheumatic diseases: pathophysiology and targeted therapy. Curr Pharm Design 2012; 18:1465-1477.
52. Provan SA, Semb AG, Hisdal J, et al. Remission is the goal for cardiovascular risk management in patients with rheumatoid arthritis: a cross-sectional comparative study. Ann Rheum Dis 2011; 70:812-817.
53. Solomon DH, Kremer J, Curtis JR, et al. Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity. Ann Rheum Dis 2010; 69:1920-1925.
54. John H, Hale ED, Treharne GJ, et al. 'Extra information a bit further down the line': rheumatoid arthritis patients' perceptions of developing educational material about the cardiovascular disease risk. Musculoskelet Care 2009; 7:272-287.